Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

Human epidermal growth factor 2 (HER2) is a tyrosine kinase receptor that interacts with multiple signaling pathways related to cellular growth and proliferation. Overexpression or amplification of HER2 is linked to various malignancies, and there have been decades of research dedicated to targeting...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2024-08, Vol.16 (16), p.2854
Hauptverfasser:	Mo, Christiana, Sterpi, Michelle, Jeon, Hyein, Bteich, Fernand
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Apoptosis Biliary tract Biopsy Breast cancer Cancer therapies Cell growth Chemotherapy Clinical trials Colorectal cancer Cytotoxicity Development and progression Drug resistance Drug therapy Epidermal growth factor ErbB-2 protein FDA approval Gastric cancer Gastrointestinal cancer Intestine Kinases Malignancy Metastasis Monoclonal antibodies Phosphorylation Physiological aspects Protein expression Protein-tyrosine kinase receptors Proteins Review Signal transduction Small intestine Trastuzumab Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Human epidermal growth factor 2 (HER2) is a tyrosine kinase receptor that interacts with multiple signaling pathways related to cellular growth and proliferation. Overexpression or amplification of HER2 is linked to various malignancies, and there have been decades of research dedicated to targeting HER2. Despite the landmark ToGA trial, progress in HER2-positive gastrointestinal malignancies has been hampered by drug resistance. This review examines current HER2 expression patterns and therapies for gastroesophageal, colorectal, biliary tract, and small bowel cancers, while dissecting potential resistance mechanisms that limit treatment effectiveness.
ISSN:	2072-6694 2072-6694
DOI:	10.3390/cancers16162854